177Lu-PSMA Treatment Monitoring Through Serial Fast Whole-Body Tomoscintigraphies Recorded With a Latest-Generation CZT-Camera

Abstract

Abstract The tomoscintigraphy monitoring of 177Lu–prostate-specific membrane antigen (PSMA) treatment may be helpful for quality control and predicting therapeutic response. Furthermore, the drawbacks of relatively low image quality and extended recording times can be overcome by new CZT-cameras providing fast, high-quality, whole-body recordings. Although still requiring further larger-scale confirmation, the current case report demonstrates that these CZT-cameras have the potential to provide straightforward and comprehensive 177Lu-PSMA treatment monitoring, that is, <20-minute whole-body tomoscintigraphy recording, tumor activities concordant with those from 68Ga-PSMA PET, and no requirement for any additional tracer injection.